Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3196153 | 1.00 | ALDH1A1 (0.43) | ALDH1A1MAPTSMN1; SMN2KDM4ETDP1 | |
| SCHEMBL3205645 | 0.86 | SMN1; SMN2 (0.47) | ALDH1A1MAPTSMN1; SMN2KDM4ETDP1 | |
| SCHEMBL3205642 | 0.86 | SMN1; SMN2 (0.47) | ALDH1A1MAPTSMN1; SMN2KDM4ETDP1 | |
| SCHEMBL3196786 | 0.84 | ADORA3 (0.39) | ALDH1A1MAPTSMN1; SMN2KDM4ETDP1 | |
| SCHEMBL3196779 | 0.84 | ADORA3 (0.39) | ALDH1A1MAPTSMN1; SMN2KDM4ETDP1 | |
| SCHEMBL13484980 | 0.84 | TSHR (0.45) | ALDH1A1MAPTSMN1; SMN2KDM4ETDP1 | |
| SCHEMBL13484979 | 0.78 | SMN1; SMN2 (0.40) | ALDH1A1MAPTSMN1; SMN2KDM4ETDP1 | |
| SCHEMBL4673481 | 0.77 | CA12 (0.48) | ALDH1A1MAPTSMN1; SMN2KDM4EKMT2A | |
| SCHEMBL4673488 | 0.77 | CA12 (0.48) | ALDH1A1MAPTSMN1; SMN2KDM4EKMT2A | |
| SCHEMBL1564319 | 0.76 | POLB (0.44) | ALDH1A1MAPTSMN1; SMN2KDM4ETHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666898-B2 | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors | ILYPSA, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666898-B2 | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors | ILYPSA, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666898-B2 | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors | ILYPSA, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090239896-A1 | AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239896-A1 | AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239896-A1 | AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. | 2009-09-24 | — | — | US | disclosed |
| EP-1960356-A2 | MULTIVALENT INDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | Ilypsa, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1951315-A2 | PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS | Ilypsa, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1948656-A2 | AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | Ilypsa, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135383-A1 | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135383-A1 | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2007056279-A2 | PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056279-A2 | PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056184-A2 | AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056281-A2 | MULTIVALENT INDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056281-A2 | MULTIVALENT INDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056184-A2 | AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | GPR119, INMT, PNLIP | ALDH1A1 2180/4885MAPT 3875/4885SMN1; SMN2 4718/4885 |
| US-20090239896-A1 | AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | PLA2G5, PLA2G4A, PLA2G3 | ALDH1A1 2274/4885MAPT 4879/4885SMN1; SMN2 4177/4885 |
| US-20070135383-A1 | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors | PNLIP, PLA2G2E, PLA2G3 | ALDH1A1 3723/4885MAPT 4260/4885SMN1; SMN2 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.